PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

Decades of advancements in immuno-oncology have enabled the development of current
immunotherapies, which provide long-term treatment responses in certain metastatic cancer …

IL-17A–producing γδ T cells in mice consist primarily of Vγ6+ tissue-resident cells and Vγ4+
circulating cells. How these γδ T cell subsets are regulated during homeostasis and cancer …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Immune checkpoint inhibitors (ICI) revolutionized the field of immuno-oncology and opened
new avenues towards the development of novel assets to achieve durable immune control …

Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …

Cognitive impairment is a debilitating side effect experienced by patients with cancer treated
with systemically administered anticancer therapies. With around 19.3 million new cases of …

Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune
cells to kill malignant cells. There are currently 7 medications that have been approved by …